




FIG. 1A




FIG. 1B




FIG. 1C





FIG. 1D



	LA 42F8	LA 46E11	BI-anti-VEGF	IgG
EC50	0.01490	0.3435	0.03401	0.002084

FIG. 2





FIG. 3

A



B






FIG. 4

A



B



C





FIG. 5


HUVEC proliferation CCK-8



	IgG	BI836880	LA42F8
IC50	~ 0.2425	3.812	49.41

Fig. 6

HEK 293 KDR reporter assay




	IgG	Faricimab	BI-836880	IEX04-012
IC50	0.03672	1.064	2.631	0.9586

FIG. 7

A

HUVEC proliferation CCK-8



B

HUVEC proliferation CCK-8





FIG. 8


C



	IgG	IEX04-012	Faricimab	BI-836880
IC50	~ 0.07786	0.1323	0.2592	0.5703

FIG. 8 (continued)

A



B





FIG. 9

A



B




FIG. 10




FIG. 11





FIG. 12

A

Lesion Grade in Laser induced CNV model



B

Lesion Grade in Laser induced CNV model




FIG. 13




FIG. 14





FIG. 15

A



B





FIG. 16

A



B




FIG. 17